Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study. J of Skin. 2025;9(4):s582. doi:10.25251/gdd40x24